[其他] AZ更新美國第三期臨床數據：保護力約76%

[CavendishJr (梅西♡)]

-------------------------------------------------------------------------
1.發文前請先詳閱[其他]分類發文規範，未依規範發文將受處份。
----------------------------按ctrl+y可刪除以上內容。---------------------




76% vaccine efficacy against symptomatic COVID-19

100% efficacy against severe or critical disease and hospitalisation

85% efficacy against symptomatic COVID-19 in participants aged 65 years and over



Positive high-level results from the primary analysis of the Phase III trial of 
AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specif
ied interim analysis announced on Monday 22 March 2021.

These results have been presented to the independent Data Safety Monitoring Boar
d. The primary analysis is pre-specified in the protocol and will be the basis f
or a regulatory submission for Emergency Use Authorization to the US Food and Dr
ug Administration in the coming weeks.

This primary efficacy analysis included the accrual of 190 symptomatic cases of 
COVID-19 from the 32,449 trial participants, an additional 49 cases to the previ
ously announced interim analysis. Participants were randomised on a 2:1 ratio be
tween the vaccine and placebo group.


The primary endpoint, vaccine efficacy at preventing symptomatic COVID-19 was 76
% (confidence interval (CI): 68% to 82%) occurring 15 days or more after receivi
ng two doses given four weeks apart. In addition, results were comparable across
 age groups, with vaccine efficacy of 85% (CI: 58% to 95%) in adults 65 years an
d older. A key secondary endpoint, preventing severe or critical disease and hos
pitalisation, demonstrated 100% efficacy. There were eight cases of severe COVID
-19 observed in the primary analysis with all of those cases in the placebo grou
p.

The vaccine was well tolerated, and no safety concerns related to the vaccine we
re identified.

https://bit.ly/2PvsrJO



被美國監管單位刁了一下

更新了數據

針對有症狀的保護力：76%

針對預防重症跟住院的保護力：100%

針對65歲以上有症狀的保護力：85%

與禮拜一公布的期中報告接近


總共32499位參與者

有190位有症狀者

比期中報告中的人數增加49位


AZ疫苗安全有效




--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 39.12.250.57 (臺灣)
※ 文章網址: https://www.ptt.cc/bbs/Stock/M.1616645076.A.4C9.html
推 analysis5566: 中国疫苗要打3針
→ jerrylin    : 反正就是接近80%  誰叫陳時中堅持不買輝瑞的
→ jerrylin    : 人家代理亞洲區也要拒買  真是腦子壞了
→ c8c8c8c8c8c8: 陳有堅持不買輝瑞? 代理問題不是BNT嗎?
→ c8c8c8c8c8c8: 阿幹看錯隻
推 nathan2000  : 把AZ講的跟科興的是誰啊…
推 reason825   : 看大家要相信數據相信專業的人，還是要相信無腦起鬨
→ reason825   : 帶風向的人？
推 phix        : 輝瑞保存也很難啊 超低溫
推 jjoonnyy    : 不差了， 但有95％的， 誰想打75的呢
→ jjoonnyy    : 但AZ對非洲的大概只有10％， 滿慘的
推 fourkg      :
推 rodney92    : 支那科興讚讚讚 支那gn最喜歡
→ simo520     : Az 夠便宜和運送方便。
推 sonyvaio    : 還是輸給嬌生 輝瑞 莫德納 只贏中國科科
推 wang111283  : 可以打一劑誰要兩劑
→ SRadiant    : 嬌生疫苗VE=66%，雖然只要一劑，但這個輸贏要怎麼
→ SRadiant    : 比？
→ matlab1106  : 死掉當然就不會感染病毒了
推 aegis43210  : 嬌生對變種病毒比較強且報告完整
推 aegis43210  : BNT有中資不好買就算了，台灣五月就能拿到莫德納，
→ aegis43210  : 民眾要快點習慣台灣有本土確診
→ SRadiant    : 對於Novavax和強生，針對B.1.351的功效均降至60％以
→ SRadiant    : 下。該疫苗針對變種毒株的真正功效尚不清楚，因為他
→ SRadiant    : 們測試了原始變種和新變種的混合。
→ SRadiant    : 針對南非變異株的試驗還沒多少完整的報告，嬌生也一
→ SRadiant    : 樣，試驗當下不同病毒株流行的程度不同，就會影響
→ SRadiant    : 整體結果。下降是一定的，但下降到多少，目前就AZ
→ SRadiant    : 很明確"無效"，其他幾家只有中和抗體的結果
推 Robben      : 95%的比較貴
→ Robben      : BNT還要冷鏈 又不是功能最強就賣最好
推 analysis5566: 德國打BNT疫苗，最近疫情卻升高
→ analysis5566: 德國截至22日，過去一周每10萬人有107人確診，超出
→ analysis5566: 重症加護病房負荷門檻。